Relay Therapeutics to Present Initial Clinical Data on Zovegalisib at Vascular Anomalies Conference

The company will share results from a study of its PI3Kα inhibitor in patients with PIK3CA-driven vascular malformations.

Apr. 3, 2026 at 5:28am

Got story updates? Submit your updates here. ›

A minimalist, glowing neon outline depicting the complex structure of the human vascular system, conceptually representing the targeted approach of Relay Therapeutics' drug candidate for treating genetic vascular disorders.Relay Therapeutics' investigational PI3Kα inhibitor aims to treat the underlying genetic drivers of vascular anomalies.Cambridge Today

Relay Therapeutics, a clinical-stage precision medicine company, announced that it will present initial clinical results and preclinical data for its investigational drug zovegalisib (RLY-2608) in vascular anomalies at the upcoming International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026. The company plans to report data on approximately 20 efficacy-evaluable patients.

Why it matters

Zovegalisib is a mutant-selective PI3Kα inhibitor that has the potential to address a significant portion of the estimated 170,000 patients with vascular anomalies driven by a PI3Kα mutation per year in the United States. The presentation of these initial clinical results will be an important milestone in the development of this targeted therapy for this underserved patient population.

The details

Relay Therapeutics developed zovegalisib using its Dynamo® platform, which enabled the discovery of the first known allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor. The company solved the full-length cryo-EM structure of PI3Kα and performed computational simulations to elucidate conformational differences between wild-type and mutant PI3Kα, informing the design of zovegalisib to overcome the limitations of traditional PI3Kα inhibitors.

  • The ISSVA World Congress 2026 will take place from May 19-22, 2026 in Philadelphia.
  • Relay Therapeutics will present the late-breaking clinical abstract on Wednesday, May 20 at 4:30 p.m. ET.
  • The company will also present a preclinical abstract on Friday, May 22 at 11:10 a.m. ET.

The players

Relay Therapeutics, Inc.

A clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease.

Zovegalisib (RLY-2608)

Relay Therapeutics' lead program, an investigational mutant-selective PI3Kα inhibitor that is being evaluated in multiple studies, including a Phase 1/2 study in patients with PIK3CA (PI3Kα) mutation-driven vascular anomalies.

International Society for the Study of Vascular Anomalies (ISSVA)

An international organization dedicated to the study and treatment of vascular anomalies.

Got photos? Submit your photos here. ›

What’s next

Relay Therapeutics plans to continue the clinical development of zovegalisib in patients with PIK3CA-driven vascular anomalies, with the goal of potentially bringing this targeted therapy to this underserved patient population.

The takeaway

The presentation of initial clinical data on zovegalisib, Relay Therapeutics' mutant-selective PI3Kα inhibitor, at the ISSVA World Congress 2026 represents an important milestone in the development of a potentially transformative therapy for patients living with PI3Kα-driven vascular anomalies.